Olanzapine versus chlorpromazine in the treatment of schizophrenia: A pooled analysis of four 6-week, randomized, open-label studies in the middle east and North Africa

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 329-337

  Dossenbach, Martin ^a,c   Treuer, Tamás ^b   Kryzhanovskaya, Ludmila ^c   Saylan, Mete ^d   Dominguez, Svetlana ^c   Huang, Xiaohong ^c,e,f  

^a Eli Lilly Austria Medical Department   (Austria)

^b Eli Lilly Regional GmbH   (Austria)

^c ELI LILLY AND COMPANY   (United States)

^d Eli Lilly   (Turkey)

^e SANOFI   (France)

^f Sanofi Aventis

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; OLANZAPINE;

ABNORMAL DREAMING; ADULT; AKATHISIA; APPETITE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AFRICA, NORTHERN; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROMAZINE; DYSKINESIA, DRUG-INDUCED; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 34447518806     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3180ca83b1     Document Type: Article

References (30)

1. El Hefny F, Al Haddad MK, Mathur V. Utilisation of psychotropic drugs in patients of the long stay ward. Pharmacoeconomics. 1992;1:203-206.
2. Lin CH, Chen MC, Wang SY, et al. Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J Formos Med Assoc. 2004;103:437-441.
3. Thornley B, Rathbone J, Adams CE, et al. Chlropromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2003;2:CD000284.
4. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155:914-920.
5. Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999;60:41-44. Erratum in: J Clin Psychiatry 1999;60:341.
6. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96:265-273.
7. Abidi S, Bhaskara SM. From chlorpromazine to clozapine - antipsychotic adverse effects and the clinician's dilemma. Can J Psychiatry. 2003;48:749-755.
8. Dunlop BW, Sternberg M, Phillips LS, et al. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull. 2003;37:99-117.
9. Hedenmalm K, Hägg S, Ståhl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf. 2002;25:1107-1116.
10. Lambert BL, Chang KY, Tafesse E, et al. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol. 2005;25:12-18.
11. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004;26:1936-1946.
12. Hong CJ, Chen JY, Chiu HJ, et al. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol. 1997;12:123-130.
13. Lieberman J, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003. Epub 2003 Mar 26.
14. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
15. Guy W. ECDEU assessment manual for psychopharmacology, revised. Bethesda MD: US Department of Health, Education, and Welfare; 1976.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
17. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;76:1-100.
18. Lang T, Secic M. How to report statistics in medicine: annotated guidelines for authors, editors, and reviewers. Philadelphia, PA: American College of Physicians; 1997.
19. Rahlfs VW, Zimmerman H. Ordinal data with few categories: how should they be analyzed? Drug Information Journal. 1993;27:1227-1240.
20. Kostakoǧlu EA, Alptekin K, Binnur Kivircik B, et al. Şizofrenik Hastalarda Olanzapin ve Klorpromazinin Etki ve Güvenliǧinin Karşilaştirilmasi. Türk Psikiyatri Dergisi. 2001;12:3-16 [In Turkish].
21. Kostakoglu E, Alptekin K, Binnur Kivircik B, et al. Olanzapine vs. chlorpromazine - 6 weeks treatment of acute schizophrenia. Eur Neuropsychopharmacol. 2001;11(suppl 3):S369-S370.
22. Kostakoglu E, Alptekin K, Binnur Kivircik B, et al. Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. Eur Neuropsychopharmacol. 2001;11(suppl 3):S369.
23. Loza N, El-Dosoky AM, Okasha TA, et al. Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol. 1999;9(suppl 5):S291.
24. Tollefson GD, Taylor CC. Olanzapine: Preclinical and clinical profiles of a novel antipsychotic agent. CNS Drug Rev. 2000;6:303-363.
25. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry. 2001;62:757-771.
26. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
27. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58(suppl 10):13-17.
28. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
29. Kato MM, Goodnick PJ. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother. 2001;2:1571-1582.
30. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.